Charcot-Marie-Tooth Disease Type I Market - Global Industry Analysis

Charcot-Marie-Tooth Disease Type I Market By Type ( PXT3003 (Pharnext) and ACE-083 (Acceleron) By Therapy( Physical Therapy, Occupational Therapy, Others) Global Industry Perspective, Comprehensive Analysis and Forecast, 2021 – 2028

Published Date: 27-Oct-2021 Category: Healthcare Report Format : PDF Pages: 150 Report Code: ZMR-6799 Status : Published

The global charcot-marie-tooth disease type I market accounted for USD 480.72 in 2020 and is expected to reach USD 632.16 Million by 2028, growing at a CAGR of 3.5% from 2021 to 2028.

Description

Market Overview

The global charcot-marie-tooth disease type I market accounted for USD 480.72 in 2020 and is expected to reach USD 632.16 Million by 2028, growing at a CAGR of 3.5% from 2021 to 2028.

Charcot-Marie-Tooth disease (CMT) is a disease that affects and damages the peripheral nerves that function as a transmit information and signals from the brain and spinal cord to and from the rest of the body, as well as sensory information such as touch back to the spinal cord and brain. CMT can also directly harm the nerves that control the muscles. Increasing muscle weakness thus becomes noticeable in adolescence or early adulthood, but certain types of disease can occur at any age. As the longer nerves are affected first, symptoms normally begin in the feet and lower legs and later can affect the fingers, hands, and arms. Most people with CMT have some amount of physical disability.

Global Charcot-Marie-Tooth Disease Type I Market Size

COVID-19 Impact Analysis

It’s been more than a year now, the COVID-19 outbreak was encountered globally and during this time, the world has suffered through unprecedented COVID-19 outbreak, several times, posing social, health, and economic emergency. Physical therapy, disease treatment, and research and development activities are some of the severely affected areas of healthcare R&D and Charcot Marie Tooth Disease Type 1A market due to COVID-19 outbreak. With travel, transport, and import-export restrictions on board and ban on local movement, people were stuck at places from where they couldn’t attend laboratories and offices for months which has made vaccine production and supply chain companies to lose enormous revenue in first 3 quarters of 2020. Research & development activities across healthcare sector have suffered enormous backlash due to stoppage of supply of raw materials for research and development and manufacturing. Investments in the animal welfare and vaccination programs and healthcare development, were held or pulled out, causing severe financial tensions.

Growth Factors

 CMT1A is a very rare type of neuromuscular disorder for which drug therapy is in development phase and clinical stage and currently there is unavailability of precise drug therapy. General therapy including physical therapy and occupational therapy is highly adopted for symptom management of CMT1A. General physical therapy is inexpensive in nature, physiotherapists are widely available, and medical devices and braces are used in physical therapy, which makes it highly effective in treating symptoms and pain management in CMT1A. Over the next few years, overall market for physical therapy segment for CMT1A treatment is expected to grow exponentially

Moreover, number of drug therapies are in development and preclinical stage, which are expected to launch at the start of next decade. With these launches, initially the overall market will grow exponentially as drug therapy rates will decline due to increasing competition in market and drug therapy adoption will increase.

.Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Type Segment Analysis Preview

PXT3003 by Pharnext segment held a share of around 77% in 2020. This is attributable as these therapies will be one of the firsts to hit the global market, where initially they will be launched in North America and Europe. These drug therapies are precise in nature and treat CMT1A disease. But on the other hand, these therapies are expected to be highly expensive in nature, due to which minimal number of patients would be able to afford it. Other patients will have to rely on medical insurances to get treated with such precise therapies. Market for these drug therapies is expected to grow exponentially from the mid of this decade.

Global Charcot-Marie-Tooth Disease Type I Market Share

Therapy Industry Segment Analysis Preview

Physical therapy segment will grow at a CAGR of over41.97% from 2021 to 2028. This is attributable Currently, physical therapy, occupational therapy, and other therapies, are used for treating symptoms of CMT1A disease. In other therapies, pain management is the most widely used physical therapy, which provides great relief to patients. General physical exercises, braces, and orthopaedic medical devices are also used in treatment of symptoms of CMT1A. Precise medical devices and braces are in development to be used during physical therapy sessions, which is expected to drive the overall physical therapy segments.

Regional Analysis Preview

North America region held a share of 37.47% in 2020. This is attributable to the presence of top companies such as The National Institutes of Health, among others. Moreover, the increasing usage of therapies is expected to generate huge demand for the market in this region.

The Europe region is projected to grow at a CAGR of 26.29% over the forecast period. Whichever therapies are currently adopted for treatment are general physiotherapy techniques which also includes use of physical therapy medical devices and orthopaedic braces. Clinical trials for drug therapies are not yet conducted in few of the regions including Asia Pacific, the Middle East, & Africa, which has given a way to the physical therapies to be adopted by the patients on large scale. Adoption for such physical therapies is at greater level in these regions, driving the physical therapy treatment market for CMT1A.

.Global Charcot-Marie-Tooth Disease Type I Market Regional Analysis

Key Market Players & Competitive Landscape

Some of key players in Charcot-Marie-Tooth Disease Type I market are Acceleron Pharma, Genzyme (A Sanofi Company), Inflectis Bioscience, Ionis Pharmaceuticals, The National Institutes of Health, among others. 

In March of 2014, the CMTA entered an alliance with Ionis Pharmaceuticals (Ionis), a leading company in the development of Anti-Sense-Oligonucleotide (ASO) therapies. ASOs are short synthetic pieces of chemically modified nucleic acids (DNA or RNA) designed to bind to the RNA that codes for a protein. Once the ASO binds to the RNA it causes the destruction of the RNA by cellular enzymes, effectively leading to a decrease in the amount of targeted protein that is expressed. Ionis had previously demonstrated the ability to deliver an ASO to peripheral nerves and wanted to work with the CMTA to design a therapy that would decrease PMP22 protein levels in CMT1A patients. Specific ASOs were designed which proved effective in altering PMP22 RNA levels in two different rodent models of CMT1A.

In September 2014, the CMTA entered an alliance with Genzyme, a Sanofi company, to test their large libraries of molecules to identify those that dampen the known disease defect in CMT1A. A screening test capable of the automation required for this work was developed in a collaboration between the University of Wisconsin and the NIH. Following testing of close to 2 million molecules at Sanofi, a number of chemical classes were identified that suppress the overexpression of PMP22, a key protein implicated in the causation of CMT1A.

The global charcot-marie-tooth disease type I market is segmented as follows:

By Type

  • PXT3003 (Pharnext)
  • ACE-083 (Acceleron)

By Therapy

  • Physical Therapy
  • Occupational Therapy
  • Others PXT3003 (Pharnext)

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 : Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Introduction
  • Chapter No. 2 : Charcot-Marie-Tooth Disease Type I Drug Market
    • 2.1. Scope
    • 2.2. Market Snapshot
    • 2.3. Global Charcot-Marie-Tooth Disease Type I Drug Market, 2025 – 2032 (USD Million)
    • 2.4. Global Charcot-Marie-Tooth Disease Type I Drug Market, 2025 – 2032 (USD Million), By Regions
      • 2.4.1. Global Market Revenue, By Region, 2025 – 2032 (USD Million)
      • 2.4.2. North America
      • 2.4.3. Europe
      • 2.4.4. Rest of World
    • 2.5. Global Charcot-Marie-Tooth Disease Type I Drug Market, 2025 – 2032 (USD Million), By Drug Type
      • 2.5.1. Global Market Revenue, By Drug Type, 2025 – 2032 (USD Million)
      • 2.5.2. PXT3003 (Pharnext)
      • 2.5.3. ACE-083 (Acceleron)
    • 2.6. Potential Driver
      • 2.6.1. Less Competitive Market
    • 2.7. Potential Restraint
      • 2.7.1. High Cost of Drug Therapy
    • 2.8. Opportunities
      • 2.8.1. Rapid Development of Novel Therapies
    • 2.9. PESTEL
      • 2.9.1. Pulitical
      • 2.9.2. Economic
      • 2.9.3. Social
      • 2.9.4. Technulogical
      • 2.9.5. Environmental
      • 2.9.6. Legislative
  • Chapter No. 3 : Charcot-Marie-Tooth Disease Type I Market
    • 3.1. Scope
    • 3.2. Market Snapshot
    • 3.3. Global Charcot-Marie-Tooth Disease Type I Market, 2016 – 2028 (USD Million)
      • 3.3.1. Global Charcot-Marie-Tooth Disease Type I Market, 2016 – 2028 (USD Million), By Regions
        • 3.3.1.1. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
      • 3.3.2. Global Market Revenue, By Therapy, 2016 – 2028
    • 3.4. North America
      • 3.4.1. North America Market Revenue, By Therapy, 2016 – 2028
    • 3.5. Europe
      • 3.5.1. Europe Market Revenue, By Therapy, 2016 – 2028
    • 3.6. Asia Pacific
      • 3.6.1. Asia Pacific Market Revenue, By Therapy, 2016 – 2028
    • 3.7. MEA
      • 3.7.1. MEA Market Revenue, By Therapy, 2016 – 2028
    • 3.8. Latin America
      • 3.8.1. Latin America Market Revenue, By Therapy, 2016 – 2028
    • 3.9. Driver
      • 3.9.1. Adoption of Physical Therapy Due to Unavailability of Precise Therapy
    • 3.10. Restraint
      • 3.10.1. Marketing & Launch of Plethora of Drugs
    • 3.11. Opportunity
      • 3.11.1. Development of Precise Medical Devices and Orthopedic Braces
    • 3.12. COVID-19 Impact
      • 3.12.1. Impact of COVID-19 on Global Charcot Marie Tooth Disease Type 1A Market
      • 3.12.2. Post-COVID Scenario: Charcot Marie Tooth Disease Type 1A Market
      • 3.12.3. Situation Post COVID-19 Vaccination Arrival
    • 3.13. Porters Five Forces Analysis
      • 3.13.1. Moderate Bargaining Power of Suppliers
      • 3.13.2. Bargaining Power of Buyers
      • 3.13.3. Threat of New Entrants
      • 3.13.4. Threat of Substitutes
      • 3.13.5. Competitive Rivalry
  • Chapter No. 4 : Competitive Analysis and Pipeline Analysis
    • 4.1. Pipeline Analysis
    • 4.2. Acceleron Pharma
    • 4.3. Genzyme (A Sanofi Company)
    • 4.4. Inflectis Bioscience
    • 4.5. Ionis Pharmaceuticals
    • 4.6. The National Institutes of Health (U.S.)
  • Chapter No. 5 : Research Methodulogy
    • 5.1. Research Methodulogy
    • 5.2. Phase I - Secondary Research
    • 5.3. Phase II - Data Modeling
      • 5.3.1. Company Share Analysis Model
      • 5.3.2. Revenue Based Modeling
    • 5.4. Phase III - Primary Research

Table Of Figures

List of Figures

FIG NO. 1. Global Charcot-Marie-Tooth Disease Type I Drug Market Revenue, 2025-2032 (USD Million)
FIG NO. 2. North America Charcot-Marie-Tooth Disease Type I Drug Market, Revenue (USD Million) 2025 – 2032
FIG NO. 3. Europe Charcot-Marie-Tooth Disease Type I Drug Market, Revenue (USD Million) 2025 – 2032
FIG NO. 4. Rest of World Charcot-Marie-Tooth Disease Type I Drug Market, Revenue (USD Million) 2025 – 2032
FIG NO. 5. Global Charcot-Marie-Tooth Disease Type I Drug Market, by PXT3003 (Pharnext), Revenue (USD Million) 2025– 2032
FIG NO. 6. Global Charcot-Marie-Tooth Disease Type I Drug Market, by ACE-083 (Acceleron), Revenue (USD Million) 2025– 2032
FIG NO. 7. Global Charcot-Marie-Tooth Disease Type I Market Revenue, 2016-2028 (USD Million)
FIG NO. 8. North America Charcot-Marie-Tooth Disease Type I Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 9. Europe Charcot-Marie-Tooth Disease Type I Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 10. Asia Pacific Charcot-Marie-Tooth Disease Type I Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 11. MEA Charcot-Marie-Tooth Disease Type I Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 12. Latin America Charcot-Marie-Tooth Disease Type I Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 13. Research Methodology – Detailed View
FIG NO. 14. Research Methodology
 


Table Of Tables

List of Tables

TABLE NO. 1. Global Charcot-Marie-Tooth Disease Type I Drug Market: Snapshot
TABLE NO. 2. Global Charcot-Marie-Tooth Disease Type I Drug Market Revenue, By Region, 2025 – 2032 (USD Million)
TABLE NO. 3. Global Charcot-Marie-Tooth Disease Type I Drug Market Revenue, By Drug Type, 2025 – 2032 (USD Million)
TABLE NO. 4. Global Charcot-Marie-Tooth Disease Type I Drug Market: Snapshot
TABLE NO. 5. Global Charcot-Marie-Tooth Disease Type I Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 6. North America Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)
TABLE NO. 7. North America Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)
TABLE NO. 8. Europe Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)
TABLE NO. 9. Asia Pacific Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)
TABLE NO. 10. MEA Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)
TABLE NO. 11. Latin America Charcot-Marie-Tooth Disease Type I Market Revenue, By Therapy, 2016 – 2028 (USD Million)

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global global charcot-marie-tooth disease type I market was valued at USD 480.72 Million in 2020.

The global global charcot-marie-tooth disease type I market is expected to reach USD 632.16 Million by 2028, growing at a CAGR of 3.5% between 2021 to 2028.

Some of the key factors driving the global charcot-marie-tooth disease type I market growth are highly adopted for symptom management of CMT1A, widely available.

 

North America region held a substantial share of the 37.47% market in 2020. This is attributable to the presence of major players such as The National Institutes of Health, among others. Europe region is projected to grow at a significant rate owing to the rising demand for 26.29% in developing economies.

Some of the major companies operating in the charcot-marie-tooth disease type I market are are Acceleron Pharma, Genzyme (A Sanofi Company), Inflectis Bioscience, Ionis Pharmaceuticals, The National Institutes of Health, among others.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed